Get the Stockscreener App
22.17
0.59%
0.2318
Kodiak Sciences Inc stock is traded at $22.17, with a volume of 16,628.
It is up +0.59% in the last 24 hours and up +21.77% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$21.94
Open:
$21.87
24h Volume:
16,628
Relative Volume:
0.02
Market Cap:
$1.18B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-5.8968
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-4.00%
1M Performance:
+21.77%
6M Performance:
+513.06%
1Y Performance:
+197.04%
1-Day Range:
$21.87
$22.49
1-Week Range:
$21.24
$23.63
52-Week Range:
$1.92
$23.63
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
22.17 | 1.16B | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.11 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
736.93 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.48 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.47 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
212.19 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Will Kodiak Sciences Inc. (K27) stock beat Nasdaq index returns2025 Institutional Moves & Weekly Market Pulse Updates - Newser
Does Kodiak Sciences Inc. (K27) stock trade below intrinsic valueInflation Watch & Technical Pattern Alert System - Newser
Kodiak Sciences Inc Stock Analysis and ForecastStop Loss Placement Tips & Explosive Capital Gains - earlytimes.in
Kodiak Sciences (KOD) Price Target Increased by 71.43% to 8.16 - MSN
Brokerages Set Kodiak Sciences Inc. (NASDAQ:KOD) Target Price at $22.67 - Defense World
Kodiak Sciences stock hits 52-week high at 22.14 USD By Investing.com - Investing.com Nigeria
Kodiak Sciences stock hits 52-week high at 22.14 USD - Investing.com
Nothing is Better Than Kodiak Sciences Inc (KOD) stock at the moment - Setenews
What analysts say about Kodiak Sciences Inc K27 stockSell Signals and Alerts & Free Risk Assessment and Control - earlytimes.in
Why Kodiak Sciences (KOD) Is Gaining Attention After Promising KSI-101 Results and Conference Spotlight - Sahm
Is Kodiak Sciences Inc. (K27) stock prepared for digital transitionMarket Sentiment Summary & Long-Term Safe Investment Ideas - newser.com
How Kodiak Sciences Inc. (K27) stock reacts to monetary easingJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Does Kodiak Sciences Inc. show high probability of reboundMarket Performance Summary & AI Driven Price Forecasts - newser.com
FY2025 EPS Forecast for Kodiak Sciences Lowered by Analyst - Defense World
What downside risks could hit Kodiak Sciences Inc. (K27) stockTrade Performance Summary & Growth Focused Entry Point Reports - newser.com
Is Kodiak Sciences Inc. (K27) stock testing key supportFed Meeting & Real-Time Chart Pattern Alerts - newser.com
HC Wainwright Expects Reduced Earnings for Kodiak Sciences - Defense World
Best data tools to analyze Kodiak Sciences Inc. stockEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
How analysts revise price targets for Kodiak Sciences Inc. (K27) stockTrade Exit Report & Technical Entry and Exit Alerts - newser.com
Kodiak Sciences (KOD): Assessing Valuation Following Q3 Losses and Advancing Pipeline Investment - Sahm
Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
How Kodiak Sciences Inc. (K27) stock valuation compares with sectorPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Will Kodiak Sciences Inc. (K27) stock outperform foreign stocksCPI Data & Weekly Top Performers Watchlists - newser.com
Chardan Capital Maintains Kodiak Sciences (KOD) Neutral Recommendation - Nasdaq
Kodiak Sciences stock hits 52-week high at 21.18 USD By Investing.com - Investing.com Nigeria
Kodiak Sciences : Jefferies Global Healthcare Conference London November 2025 - MarketScreener
Kodiak Sciences stock hits 52-week high at 21.18 USD - Investing.com
KOD Maintains Neutral Rating by Chardan Capital | KOD Stock News - GuruFocus
Kodiak Sciences stock price target raised to $26 from $24 at H.C. Wainwright - Investing.com India
KOD: HC Wainwright Maintains Buy Rating, Raises Price Target to $26 | KOD Stock News - GuruFocus
HC Wainwright & Co. Maintains Kodiak Sciences (KOD) Buy Recommendation - Nasdaq
Kodiak Sciences (KOD) Price Target Increased by 43.82% to 18.19 - Nasdaq
How to manage a losing position in Kodiak Sciences Inc.Market Risk Summary & Safe Swing Trade Setup Alerts - newser.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):